MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

RS-127445

CAS No. : 199864-87-4

MCE 站：RS-127445

产品活性：RS-127445 是一种有效的，具有口服活性的，高亲和力选择性 5-HT_2B 受体拮抗剂，pK_i 为 9.5，比作用于其他受体和离子通道的选择性高 1000 倍。

研究领域：GPCR/G Protein  |  Neuronal Signaling

作用靶点：5-HT Receptor

In Vitro: RS-127445 is found to has nanomolar affinity for the 5-HT_2B receptor (pK_i=9.5±0.1) and 1,000 fold selectivity for this receptor as compared to numerous other receptor and ion channel binding sites. RS-127445 potently displaces [³H]-5-HT from human recombinant 5-HT_2B receptors expressed in CHO-K1 cells. The affinity (pK_i value) of RS-127445 for the 5-HT_2B receptor is 9.5±0.1 (n=9). RS-127445 is selective for the 5-HT_2B receptor, having approximately 1000 fold lower affinity for the human recombinant 5-HT_2A, 5-HT_2C, 5-HT₅, 5-HT₆ and 5-HT₇ receptors, a 5-HT_1A receptor in rat brain membranes, a 5-HT_1B/D receptor in bovine caudate, and a monoamine uptake site in rabbit platelets. RS-127445 potently blocks the 5-HT (10 nM) evoked increases in intracellular calcium concentrations in the HEK-293 cells expressing the 5-HT_2B receptor (pIC₅₀ of 10.4±0.1). In cells expressing human recombinant 5-HT_2B receptors, RS-127445 potently antagonizes 5-HT-evoked formation of inositol phosphates (pK_B=9.5±0.1) and 5-HT-evoked increases in intracellular calcium (pIC₁₀=10.4±0.1). RS-127445 also blocks 5-HT-evoked contraction of rat isolated stomach fundus (pA_2B=9.5±1.1) and (±)α-methyl-5-HT-mediated relaxation of the rat jugular vein (pA₂=9.9±0.3).

In Vivo: In rats, the fraction of RS-127445 that is bioavailable via the oral or intraperitoneal routes is 14 and 60% respectively. Intraperitoneal administration of RS-127445 (5 mg/kg) produced plasma concentrations predicted to fully saturate accessible 5-HT_2B receptors for at least 4 h.RS-127445 (5 mg/kg) is administered to rats by oral, intraperitoneal and intravenous routes. Peak plasma concentrations are rapidly achieved with the highest concentrations being found at the first time-point measured following intravenous and intraperitonael administration (0.08 h) and by 0.25 h following dosing by the oral route of administration. RS-127445 is cleared from plasma with an estimated terminal elimination half-life of approximately 1.7 h. The bioavailability of RS-127445, when administered by the oral and intraperitoneal routes is approximately 14 and 62% of that obtained by intravenous administration. Approximately 60% of an intraperitoneal dose and 14% of the oral dose of RS-127445 (5 mg/kg) is bioavailable. RS-127445 (1-30 mg/kg), dose-dependently reduces faecal output, reaching significance at 10 and 30 mg/kg (n=6-11). In blood and brain, >98% of RS-127445 is protein-bound.

相关产品：Harmine  |  SCH-23390 hydrochloride  |  Puerarin  |  Olanzapine  |  GTS-21 dihydrochloride  |  Thioridazine hydrochloride  |  Risperidone  |  SB-269970 hydrochloride  |  Dihydroergotamine mesylate  |  Amitriptyline hydrochloride  |  Aripiprazole  |  Ketanserin  |  WAY-100635 Maleate  |  Buspirone hydrochloride  |  Cisapride  |  Methiothepin mesylate  |  Trazodone hydrochloride  |  Pindolol  |  Quetiapine  |  Lumateperone tosylate  |  Perphenazine  |  8-OH-DPAT  |  Levomepromazine  |  SB-224289 hydrochloride  |  Volinanserin  |  Ziprasidone  |  Paliperidone  |  Sertindole  |  Alprenolol hydrochloride  |  Asenapine maleate

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。